Oppenheimer Weighs in on Motus GI Holdings, Inc.’s Q1 2022 Earnings (NASDAQ:MOTS)

Motus GI Holdings, Inc. (NASDAQ:MOTSGet Rating) – Oppenheimer issued their Q1 2022 earnings per share (EPS) estimates for Motus GI in a report issued on Monday, April 25th. Oppenheimer analyst S. Lichtman expects that the company will post earnings of ($0.11) per share for the quarter. Oppenheimer also issued estimates for Motus GI’s Q2 2022 earnings at ($0.12) EPS and Q4 2022 earnings at ($0.13) EPS.

Motus GI (NASDAQ:MOTSGet Rating) last issued its quarterly earnings results on Tuesday, March 29th. The company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.01. Motus GI had a negative return on equity of 83.71% and a negative net margin of 4,867.77%. During the same quarter in the prior year, the business earned ($0.12) earnings per share.

A number of other brokerages also recently commented on MOTS. Alliance Global Partners decreased their price target on Motus GI from $1.75 to $1.40 in a research report on Wednesday, January 26th. Colliers Securities reaffirmed a “buy” rating on shares of Motus GI in a research report on Tuesday, March 22nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $1.48.

Shares of MOTS opened at $0.26 on Wednesday. The company has a current ratio of 8.26, a quick ratio of 8.09 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $14.34 million, a price-to-earnings ratio of -0.48 and a beta of 2.40. The stock has a 50 day moving average of $0.34 and a 200 day moving average of $0.45. Motus GI has a 12 month low of $0.26 and a 12 month high of $1.62.

A number of large investors have recently added to or reduced their stakes in the business. Morgan Stanley increased its position in Motus GI by 41.7% in the second quarter. Morgan Stanley now owns 51,000 shares of the company’s stock worth $53,000 after buying an additional 15,000 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Motus GI by 20.4% in the third quarter. Millennium Management LLC now owns 118,652 shares of the company’s stock worth $82,000 after acquiring an additional 20,110 shares during the period. BlackRock Inc. boosted its holdings in shares of Motus GI by 13.5% in the third quarter. BlackRock Inc. now owns 202,808 shares of the company’s stock worth $139,000 after acquiring an additional 24,100 shares during the period. Citadel Advisors LLC boosted its holdings in shares of Motus GI by 276.3% in the second quarter. Citadel Advisors LLC now owns 46,447 shares of the company’s stock worth $48,000 after acquiring an additional 34,103 shares during the period. Finally, LPL Financial LLC bought a new position in shares of Motus GI in the fourth quarter worth $25,000. 13.36% of the stock is owned by institutional investors and hedge funds.

About Motus GI (Get Rating)

Motus GI Holdings, Inc, a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.

Featured Stories

Earnings History and Estimates for Motus GI (NASDAQ:MOTS)

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.